Ardea Biosciences Inc

Ardea Biosciences — Corporate Update (March 2008)

28 slides from Ardea Biosciences's corporate update, Mar 18, 2008

  1. Slide 1: Barry D. Quart, PharmD President & Chief Executive Officer

    Barry D. Quart, PharmD President & Chief Executive Officer NASDAQ: RDEA March 18, 2008

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results

  3. Slide 3: Investment Highlights

    Investment Highlights Four NCEs in clinical trials by early 2008 Initial efficacy results in three indications during 2008 Phase 2a HIV results with RDEA806 Phase 2 gout results with RDEA806 Phase 1 cancer results with RDEA119 Addressing multi-billion-dollar markets HIV Gout Cancer Inflammatory dise

  4. Slide 4: Pipeline Addresses Major Markets

    Pipeline Addresses Major Markets RDEA806 2nd NNRTI RDEA806 RDEA119 RDEA119 2nd MEKI Discovery Preclinical Phase 0/1 Phase 2 Phase 3 NNRTI for HIV HIV Gout MEKI for Cancer MEKI for Inflammation Cancer/Inflammation 7

  5. Slide 5: HIV Market Opportunity

    HIV Market Opportunity Over $8 billion mature market focused on safety and convenience Highest success rate in Phase 3 of any class Three primary classes of therapies: 10 approved protease inhibitors (PIs) 11 nucleosides (NRTIs; single agents and combinations) Only 4 approved non-nucleosides (NNRTIs

  6. Slide 6: RDEA806 vs. Target Product Profile

    RDEA806 vs.Target Product Profile Highly active against efavirenz-resistant strains High genetic barrier to resistance Better safety profile than efavirenz (or competitors) Reduced CNS toxicity (no abnormal dreams or significant dizziness) Improved lipid profile (does not increase cholesterol or tri

  7. Slide 7: Phase 2a ART Naive Proof-of-Concept Study

    Phase 2a ART Naive Proof-of-Concept Study Study RDEA806-201 ART-Naive Monotherapy Primary Endpoint Change from baseline in plasma VL Secondary Endpoints VL decay rate, CD4 and CD8 changes, PK/PD, safety, tolerability, genotypic and phenotypic resistance Location EU: Moyle (UK), Stoehr (Germany), Rie

  8. Slide 8: Phase 2a Positive Preliminary Data

    Phase 2a Positive Preliminary Data Generally well tolerated No serious adverse events reported No abnormal dreams, drug-related rash, or ECG-related adverse events Cohort 1: 400mg BID Viral load reduction on Day 8 (adjusted for placebo): 2.0 log10 Cohort 2: 600mg QD Viral load reduction on Day 8 (ad

  9. Slide 9: Study RDEA806-201: Mean Change in Viral Load

    Study RDEA806-201: Mean Change in Viral Load 17

  10. Slide 10: Study RDEA806-201: Mean Change in Viral Load Placebo Adjusted

    Study RDEA806-201: Mean Change in Viral Load Placebo Adjusted 19

  11. Slide 11: Study RDEA806-201: Mean Viral Load Change Placebo Adjusted

    Study RDEA806-201: Mean Viral Load Change Placebo Adjusted Percent < 400 copies RDEA806 400mg BID - 50 % RDEA 806 600mg QD - 50% Raltegravir 400mg BID - 50% (Day 10)* 21 *Markowitz M, et al . J Acquir Immune Defic Syndr 2006;43:509-515

  12. Slide 12: Viral Load Decline on Day (Placebo Adjusted)

    Viral Load Decline on Day 8 (Placebo Adjusted) - -1.7 - -1.6 - -1.8 - -1.9 - -1.2 - -1.6 1IDX899 Program Update February 6, 2008 2Fatkenheuer G, et al. IAS 2007 (Abstract WESS202) 3Sankatsing S, et al. AIDS 2003, 17:2623-2627 4Goebel F, et al. AIDS 2006, 20:1721-1726 5Markowitz M, et al . J Acquir I

  13. Slide 13: Preliminary Safety Results

    Preliminary Safety Results No serious adverse events No clinically significant laboratory abnormalities No discontinuations No typical NNRTI side effects: No abnormal dreams No drug-related rash No ECG-related adverse events RDEA806 (n=14) RDEA806 (n=14) Placebo (n=4) Placebo (n=4) n (%) n (%) Patie

  14. Slide 14: Improved Enteric-Coated Tablet Formulation

    Improved Enteric-Coated Tablet Formulation Phase 1 pharmacokinetic study with improved enteric-coated (EC) formulations conducted EC tablet formulation provides lower peak levels and improved 24- hour trough plasma levels and can be given with food The pk of the EC tablet at 600mg QD should equal th

  15. Slide 15: Tablet Size Comparisons with Marketed Products

    Tablet Size Comparisons with Marketed Products 1 RDEA806 EC Tablet 200 mg SUSTIVA(r) 600 mg INTELENCE(tm) 100 mg 80% Drug 50% Drug 12.5% Drug RDEA806 EC Tablet 200 mg ATRIPLA(tm) 600/200/300 mg SUSTIVA(r) 600 mg INTELENCE(tm) 100 mg 80% Drug 67% Drug 50% Drug 12.5% Drug

  16. Slide 16: Study RDEA806-202 Naive Dose Response Study

    Study RDEA806-202 Naive Dose Response Study Study Start 2Q08 (3-month animal toxicology completed; 6-month rat and 9-month monkey will be completed midyear) Primary Endpoint Proportion of patients with Plasma VL < 50 copies/mL Secondary Endpoints VL decay rate, CD4 and CD8 changes, PK, PK/PD, safety

  17. Slide 17: Conclusions

    Conclusions Preliminary data demonstrate robust antiviral effect Drug continues to be very well tolerated Human pk results from new EC formulation support moving forward with this formulation into Phase 2a Final data will be submitted for presentation at a major scientific conference Phase 2b to sta

  18. Slide 18: RDEA 2nd and 3rd Generation NNRTIs

    RDEA 2nd and 3rd Generation NNRTIs Different structural classes than RDEA806 Appear to be more potent, with greater coverage of resistant strains Potentially longer half-lives Fold-Change* in Protein Adjusted EC50 Fold-Change* in Protein Adjusted EC50 Fold-Change* in Protein Adjusted EC50 Fold-Chang

  19. Slide 19: Gout Unmet Medical Need

    Gout Unmet Medical Need About the Indication Painful and debilitating disease Inflammation Disfiguring nodules (tophi) Attacks of severe pain (flares) Kidney damage (nephropathy) Caused by abnormally elevated levels of uric acid Increasing incidence and severity in U.S. (3-5M) Early onset, especiall

  20. Slide 20: RDEA806 Significantly Reduces Serum Uric Acid

    RDEA806 Significantly Reduces Serum Uric Acid 1 0.5 0 - -0.5 - -1 - -1.5 - -2 - -2.5 Day 0 Day 3 Day 7 Day 10/14 Follow-up Change in SUA (mg/dL) Treatment Day Placebo 500 mg bid 400 mg MR bid 300 mg bid - -3 * * * * * * * * * * p<0.001 39

  21. Slide 21: Significant Correlation Between Reduction and Baseline Serum Uric Acid Values

    Significant Correlation Between Reduction and Baseline Serum Uric Acid Values Last Day of Dosing Change in SUA (mg/dL) Baseline Serum Uric Acid (mg/dL) 0.00 - -0.50 - -1.00 - -1.50 - -2.00 - -2.50 - -3.00 - -3.50 0.00 1.00 2.00 3.00 4.00 - -4.00 5.00 6.00 7.00 8.00 p=0.004 SUA > 6.8 mg/dL = hyperuri

  22. Slide 22: Next Steps in Gout

    Next Steps in Gout Two-week healthy volunteer study demonstrated biologic activity and safety Initiate Phase 2 dose-ranging study Patients with hyperuricemia and a history of gout 1H'08 Currently investigating active moiety and mechanism of action 43

  23. Slide 23: The Age of Targeted Cancer Treatments

    The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) XL518 (Ph 1) RDEA119 (Ph 1)* RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 45 *Only MEKI in clinic without large

  24. Slide 24: RDEA119 Inhibits Tumor Volume

    RDEA119 Inhibits Tumor Volume 0 10 20 30 40 Tumor volume (mm3) Days Vehicle RDEA119 25mg/kg RDEA119 50mg/kg RDEA119 100mg/kg 1200 1000 800 600 400 200 0 Dosing Period Preclinical colon cancer Xenograft model 47

  25. Slide 25: Phase 1 Advanced Cancer Study Design

    Study RDEA119 Primary Endpoint Safety, tolerability, PK Secondary Endpoints Pharmacodynamic (PD) measures: pERK, Ki67, Nras, Kras and Braf mutations; Antitumor activity by CT scan Location Von Hoff (Arizona), Weekes (UCHSC), Adjei (Roswell Park) Study Population Advanced cancer patients, all-comers

  26. Slide 26: Financial Position Summary

    Financial Position Summary Statement of Operations (In thousands, except per share data) Nine Months Ended Sept. 30, 2007 Revenue Operating expenses Interest and other income $2,827 $20,756 $1,876 NET LOSS $(16,233) NET LOSS PER SHARE $(1.67) Private placement financing completed in December 2007; $

  27. Slide 27: Near-Term Anticipated Milestones

    Near-Term Anticipated Milestones Drug Candidate Event Date HIV HIV HIV RDEA806 Phase 2a start ? 2nd Gen NNRTI FIH micro-dosing / human PK data 1Q08 RDEA806 Phase 2a results (PoC) 1Q08 ? RDEA806 Phase 2b start 2Q08 2nd Gen NNRTI* Phase 1 start 2H08 Gout Gout Gout RDEA806 Phase 2 start 2Q08 RDEA806 Ph

  28. Slide 28: NASDAQ: RDEA

    NASDAQ: RDEA

Ardea Biosciences — Corporate Update (March 2008) on 6ix